Who are ABVD q4 weeks's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): chemotherapy of mFOLFOX6 or FOLFIRI, Consolidation Chemotherapy, CVP, FEC, SOX Chemotherapy, Dexamethasona, Idarubicine, ARA-C, Methotrexate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abvd-q4-weeks.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ABVD q4 weeks — Competitive Intelligence Brief

ABVD q4 weeks (ABVD q4 weeks) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy regimen. Area: Oncology.

phase 3 Combination chemotherapy regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ABVD q4 weeks (ABVD q4 weeks) — European Organisation for Research and Treatment of Cancer - EORTC. ABVD is a combination chemotherapy regimen that uses four cytotoxic agents to kill rapidly dividing cancer cells through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and microtubule disruption.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ABVD q4 weeks TARGET	ABVD q4 weeks	European Organisation for Research and Treatment of Cancer - EORTC	phase 3	Combination chemotherapy regimen
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)
Consolidation Chemotherapy	Consolidation Chemotherapy	National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos	marketed	Combination chemotherapy regimen
CVP	CVP	SCRI Development Innovations, LLC	marketed	Combination chemotherapy regimen
FEC	FEC	Hoffmann-La Roche	marketed	Combination chemotherapy regimen
SOX Chemotherapy	SOX Chemotherapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Combination chemotherapy regimen
Dexamethasona, Idarubicine, ARA-C, Methotrexate	Dexamethasona, Idarubicine, ARA-C, Methotrexate	PETHEMA Foundation	marketed	Combination chemotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy regimen class)

Sun Yat-sen University · 5 drugs in this class
Sixth Affiliated Hospital, Sun Yat-sen University · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
University Hospital, Bordeaux · 2 drugs in this class
Beijing Friendship Hospital · 1 drug in this class
Centre Hospitalier Universitaire Dijon · 1 drug in this class
Amgen · 1 drug in this class
Chungnam National University Hospital · 1 drug in this class
AstraZeneca · 1 drug in this class
Children's Cancer Group, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABVD q4 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/abvd-q4-weeks. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab